Provided are compounds for inhibiting a hepatitis C virus (HCV), stereisomers, tautomers, isotope isomers, hydrates, esterified or amidated prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions thereof and uses thereof, as well as uses of mixtures formed by one or more of the components in the preparation of medicines for inhibiting the HCV. The compounds can effectively inhibit the hepatitis C virus NS5A, and can be used for preparing medicines for preventing and/or treating diseases of the hepatitis C virus (HCV-NS5A) infection.
